PCBMI

 
ÀÛ¼ºÀÏ : 09-12-08 16:57
PCBMI Seminar (T cell, AUTOIMMUNITY, TB) °³ÃÖ ¾È³»
 ±Û¾´ÀÌ : ÃÖ°í°ü¸®ÀÚ
Á¶È¸ : 10,120  
¾Æ·¡¿Í °°ÀÌ PCBMI Seminar¸¦ °³ÃÖÇÏ¿À´Ï °ü½ÉÀÖ´Â ¿¬±¸ÀÚ ¹× T cell, AUTOIMMUNITY, TB ¿¬±¸ °ü°èÀںеéÀÇ ¸¹Àº Âü¿© ¹Ù¶ø´Ï´Ù.

   - ÀÏ     ½Ã: 2009³â 12¿ù 11ÀÏ(±Ý) ¿ÀÀü 10:30~12:00
   - Àå     ¼Ò: Æ÷-°¡ ¿¬±¸¿ø 1205È£ ¼¼¹Ì³ª½Ç (°¡Å縯´ë ¼ºÀDZ³Á¤ ¼ºÀÇȸ°ü 12Ãþ)
   - ¹ßÇ¥¿¬ÀÚ: Paul V. Lehmann, M.D., Ph.D., Professor of Pathology at C.W.R.U, Founder, President and CEO of CTL
   - ¹ßÇ¥Á¦¸ñ: ELISPOT assays for delineation of T cell effector classes and activation states
   - Âü¿©½Åû: À̹øÁÖ ¸ñ¿äÀÏ(12.10) 15½Ã±îÁö, À̸ÞÀÏ È¸½Å(mijukim@psotehc.ac.kr, ¼Ò¼Ó, ¼º¸í, ¿¬¶ôó)
   - ÃÊ     ·Ï
During this talk I will cover our studies utilizing granzyme B, perforin, TRAIL and IFN-g ELISPOT assays for monitoring HIV-specific T cells in infected individuals, detecting antigen-specific effector, memory, and ¡°unhelpted/frustrated/lethargic¡± CD8 cells. The data draw attention to the need for multicolor ELISPOT analysis which permits to combine the strengths of the ELISPOT approach (ultra high sensitivity, robustness, need for minimal cell material, suitability for high throughput and regulated tests, and work with cryopreserved PBMC) with the need for multiplexing. I will also cover the progress we have made towards the development, optimization, and qualification of simultaneous measurements of IL-2, IL-4, IL-17 and IFN-g to assess Thpp, Th2, Th-17 and Th1 effector cell diversity within antigen-specific CD4 cell immunity. the progress we have made towards the development, optimization, and qualification of simultaneous measurements of IL-2, IL-4, IL-17 and IFN-g to assess Thpp, Th2, Th-17 and Th1 effector cell diversity within antigen-specific CD4 cell immunity.


 
   
 

Á¦¸ñ ¾øÀ½